Combining radioimmunotherapy with antihypoxia therapy 2-deoxy-D-glucose results in reduction of therapeutic efficacy

Clinical Cancer Research

Volumn 13, Issue 6, 2007, Pages 1903-1910

  Dearling, Jason L J ^a   Qureshi, Uzma ^a   Begent, Richard H J ^a   Pedley, R Barbara ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYGLUCOSE; IODINE 131; ANTINEOPLASTIC AGENT;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER THERAPY; CELL CULTURE; COLONY FORMING UNIT; COLORECTAL CARCINOMA; CYTOTOXICITY; DRUG ANTAGONISM; DRUG EFFICACY; HUMAN; HUMAN CELL; HYPOXIA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; ANIMAL; CELL HYPOXIA; COLON TUMOR; DRUG EFFECT; DRUG SCREENING; EVALUATION; FEMALE; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION EXPOSURE; SURVIVAL; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DEOXYGLUCOSE; FEMALE; HUMANS; MICE; MICE, NUDE; RADIOIMMUNOTHERAPY; SURVIVAL ANALYSIS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34250179496     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2094     Document Type: Article

References (47)

1. 131I anti-CEA antibody in a colonic xenografts model. Br J Cancer 1993;68:69-70.
2. Press OW, Eary JF, Appelbaum FR, et al. Phase II trial of I-131B1 (anti-CD20) antibody therapy with autologous stem-cell transplantation for relapsed B-cell lymphomas. Lancet 1995;346:336-40.
3. 2 antibodies. Br J Cancer 1994;70:521-5.
4. Glennie MJ, Johnson PWM. Clinical trial of antibody therapy. Immunol Today 2000;21:403-10.
5. Napier MP, Begent RHJ. Radioimmunotherapy of gastrointestinal cancer. Cancer radioimmunotherapy: In: Riva T, editor. Boston: Harwood Academia; 1998. p. 333-88.
6. Bedford JS, Hall EJ. Survival of HeLa cells cultured in vitro and exposed to protracted gamma-irradiation. Int J Radiat Biol 1964;7:377-83.
7. 192Ir at low dose rate on mammalian cells. Radiother Oncol 1987;10:247-52.
8. Spiro IJ, Ling CC, Stickler R, Gaskill J. Oxygen radio-sensitisation at low dose rate. Br J Radiol 1985;58:357-63.
9. Ling CC, Spiro IJ, Mitchell J, Stickler R. The variation of OER with dose rate. Int J Radiat Oncol Biol Phys 1985;11:1367-73.
10. 2 measured by EPR oximetry in human tumor xenografts. Radiat Res 2001;155:466-73.
11. Morton JD, Porter E, Yabuki H, Nath R, Rockwell S. Effects of a perfluorochemical emulsion on the response of BA1112 rat rhabdomyosarcomas to continuous low dose-rate irradiation. Radiat Res 1990;124:178-82.
12. Blumenthal RD, Taylor A, Osorio L, et al. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia. Int J Cancer 2001;94:564-71.
13. 131I-labeled antibody and the hypoxic cytotoxin SR 4233 in vitro and in vivo. Radiat Res 1992;132:351-8.
14. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 1995;36:1625-32.
15. Clavo AC, Wahl RL. Effects of hypoxia on the uptake of tritiated thymidine, L-leucine, L-methionine and FDG in cultured cancer cells. J Nucl Med 1996;37:502-6.
16. Burgman P, O'Donoghue JA, Humm JL, Ling CC. Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl Med 2001;42:170-5.
17. Dearling JLJ, Flynn AA, Sutcliffe-Goulden J, et al. Analysis of the regional uptake of radiolabelled deoxyglucose analogs in human tumor xenografts. J Nucl Med 2004;45:101-7.
18. 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med 2005;46:675-82.
19. Pugachev A, Ruan S, Carlin S, et al. Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys 2005;62:545-53.
20. Wick AN, Drury DR, Nakata HI, Wolfe JB. Localisation of the primary metabolic block produced by 2-deoxyglucose. J Biol Chem 1957;224:963-9.
21. 31P magnetic resonance spectroscopy. Cancer Res 1992;52:71-6.
22. Gridley DS, Nutter RL, Mantik DW, Slater JM. Hyperthermia and radiation in vivo: effect of 2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys 1985;11:567-74.
23. 4- methythiosemicarbazone) using 2-deoxy-D-glucose. Cancer Res 2003;63:5496-504.
24. Tannock IF, Guttman P, Rauth AM. Failure of 2-deoxy-D-glucose and 5-thio-D-glucose to kill hypoxic cells of two murine tumors. Cancer Res 1983;43:980-3.
25. Zhu Z, Jiang W, McGinley JN, Thompson HJ. 2-Deoxyglucose as an energy restriction mimetic agent: effects on mammary carcinogenesis and on mammary tumor. Cancer Res 2005;65:7023-30.
26. Dwarkanath BS, Jain VK. Energy linked modifications of the radiation response in a human cerebral glioma cell line. Int J Radiat Oncol Biol Phys 1989;17:1033-40.
27. Jain VK, Kalia VK, Sharma R, Maharajan V, Menon M. Effects of 2-deoxy-D-glucose on glycolysis, proliferation kinetics and radiation response of human cancer cells. Int J Radiat Oncol Biol Phys 1985;11:943-50.
28. Dwarkanath BS, Zolzer F, Chandana S, et al. Heterogeneity in 2-deoxy-D-glucose-induced modifications in energetics and radiation responses of human tumor cell lines. Int J Radiat Oncol Biol Phys 2001;50:1051-61.
29. Rodriguez-Enriquez S, Juarez O, Rodriguez-Zavala JS, Moreno-Sanchez R. Multisite control of the Crab-tree effect in ascites hepatoma cells. Eur J Biochem 2001;268:2512-9.
30. Tom BH, Rutzky LP, Jakstys MM, Oyashu R, Kaye CI, Kahan BD. Human colonic adenocarcinoma cell. I. Establishment and description of a new line. In Vitro 1976;12:180-91.
31. Burtis CA, Ashwood ER. Tietz textbook of clinical chemistry, 2nd ed. Philadelphia (PA): W.B. Saunder Company, a Division of Harcourt Brace & Co; 1994. p. 2190.
32. Lee CG, Heijn M, di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60:5565-70.
33. Hunter AJ, Blekkenhorst GH. The effects of 2-deoxyglucose and amino-oxyacetic acid on the radiation response of mammalian cells in vitro. Int J Radiat Biol 1998;73:311-24.
34. Harwood PJ, Britton DW, Southall PJ, Boxer GM, Rawlins G, Rogers GT. Mapping epitope characteristics on carcinoembryonic antigen. Br J Cancer 1986;54:75-82.
35. Simpkin DJ, Mackie TR. EGS4 Monte Carlo determination of the β dose kernel in water. Med Phys 1990;17:179-86.
36. Greenwood FC, Hunter WM. The preparation of 131-I-labelled human growth hormone of high specific radioactivity. Biochem J 1963;89:116-23.
37. Laszlo J, Humphreys SR, Goldin A. Effects of glucose analogs (2-deoxy-D-glucose, 2-deoxy-D-galactose) on experimental tumors. J Natl Cancer Inst 1960;24:267-81.
38. Pedley RB, Hill SA, Boxer GM, et al. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A4-phosphate. Cancer Res 2001;15:4716- 22.
39. Seymour CB, Mothersill C, Moriarty MJ. Glucose analogues alter the response of CHO-K1 cells to γ irradiation. Acta Radiol Oncol 1985;24:351-6.
40. Boucher Y, Lee I, Jain RK. Lack of correlation between interstitial fluid pressure and oxygen partial pressure in solid tumors. Microvasc Res 1995;50:175-82.
41. 2 measurements in one rodent and two human tumor xenografts. Radiat Res 1994;139:1-8.
42. Yamagishi N, Miyakoshi J, Takebe H. Enhanced radiosensitivity by inhibition of nuclear factor κB activation in human malignant glioma cells. Int J Radiat Biol 1997;72:157-62.
43. Liu Y, Nakahara T, Miyakoshi J, Hu D-L, Nakane A, Abe Y. Nuclear accumulation and activation of nuclear factor κB after split-dose irradiation in LS174T cells. JRadiat Res 2007;48:13-20.
44. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-κB. Annu Rev Cell Biol 1994;10:405-55.
45. Brown K, Park S, Kanno T, Franzoso G, Siebenlist U. Mutual regulation of the transcriptional activator NF-κB and its inhibitor, IκB-α. Proc Natl Acad Sci U S A 1993;90:2532-6.
46. Ledoux S, Yang R, Friedlander G, Laouari D. Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. Cancer Res 2003;63:7284-90.
47. Kalia VK. Optimizing radiation therapy of brain tumours by combination of 5-bromo-2-deoxy-uridine and 2-deoxy-D-glucose. Indian J Med Res 1999;109:182-7.